Multicenter Evaluation of the Idylla GeneFusion in Non–Small-Cell Lung Cancer
- 16 June 2022
- journal article
- research article
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 24 (9) , 1021-1030
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Meso Scale Diagnostics
- AstraZeneca
- Boehringer Ingelheim
- Bayer
- Janssen Pharmaceutica
- Merck
- Bio-Rad Laboratories
- Eli Lilly and Company
- Roche
- Amgen
- Bristol-Myers Squibb
- Abbott Laboratories
- Novartis
This publication has 33 references indexed in Scilit:
- Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK FusionsAmerican Journal of Surgical Pathology, 2017
- Targeting ALK: Precision Medicine Takes on Drug ResistanceCancer Discovery, 2017
- Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Journal of Thoracic Oncology, 2017
- Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerPLOS ONE, 2016
- NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesESMO Open, 2016
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerNature Medicine, 2013
- RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- Molecular pathology of lung cancer: key to personalized medicineLaboratory Investigation, 2012
- RET, ROS1 and ALK fusions in lung cancerNature Medicine, 2012
- EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009